Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB26FZH81
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. The contract, awarded on November 7, 2025, with an ultimate completion date of November 10, 2025, utilizes firm fixed-price pricing with no set-aside designation. Xtandi is a specialty oncology pharmaceutical used in prostate cancer treatment, reflecting the Department of Defense's need for advanced cancer therapies to support military healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded on November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. As a prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceuticals—including branded and generic prescription drugs, biologics, and medical consumables—to support Department of Defense healthcare facilities worldwide. The company's established performance across numerous delivery orders demonstrates its capability to fulfill the military medical system's specialized pharmaceutical requirements.
Quick answers
Who was awarded contract SPE2DB26FZH81?
SPE2DB26FZH81 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 7, 2025.
How much is contract SPE2DB26FZH81 worth?
The government has obligated $4,170 on SPE2DB26FZH81.
Is contract SPE2DB26FZH81 an order under another contract?
Yes. SPE2DB26FZH81 is a delivery order under SPE2DB20D9329, an indefinite delivery contract.
Was contract SPE2DB26FZH81 competed?
The extent of competition for SPE2DB26FZH81 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award